Reading view
MEDIC: Comprehensive Evaluation of Leading Indicators for LLM Safety and Utility in Clinical Applications
Large language models improve transferability of electronic health record-based predictions across countries and coding systems
npj Digital Medicine, Published online: 22 January 2026; doi:10.1038/s41746-026-02363-5
Large language models improve transferability of electronic health record-based predictions across countries and coding systemsGlobal Benchmark Database
Africa’s Digital Health Revolution: The Digital Fit-Viability Model to Move From Innovation to Scaled Implementation
A nowhere-to-hide mechanism ensures complete piRNA-directed DNA methylation
Nature, Published online: 14 January 2026; doi:10.1038/s41586-025-09940-w
In mice, a SPOCD1–TPR-dependent ‘nowhere-to-hide’ mechanism is required for complete non-stochastic piRNA-directed LINE1 DNA methylation by preventing transposons from escaping surveillance within heterochromatin.WaterCopilot: An AI-Driven Virtual Assistant for Water Management
From Wearables to Warnings: Predicting Pain Spikes in Patients with Opioid Use Disorder
BCMA-directed mRNA CAR-T cell therapy for myasthenia gravis: exploratory biomarker analysis of a placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04170-z
Analysis of a placebo-controlled trial of a BCMA-targeting CAR-T cell therapy in patients with myasthenia gravis shows that CAR-T cell infusion selectively remodels the systemic immune environment, with elimination of BCMA-high plasma cells and activated plasmacytoid dendritic cells and changes in the autoreactive B cell repertoire.BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial
Nature Medicine, Published online: 09 January 2026; doi:10.1038/s41591-025-04171-y
In a randomized, double-blind, placebo-controlled trial comparing autologous mRNA-engineered BCMA-targeting CAR T cell therapy versus placebo in patients with generalized myasthenia gravis, a significantly higher percentage of patients exhibited a reduction in disease activity in the treatment arm than in the placebo arm.Intervention in Health Misinformation Using Large Language Models for Automated Detection, Thematic Analysis, and Inoculation: Case Study on COVID-19
Digital Twin based Automatic Reconfiguration of Robotic Systems in Smart Environments
Computational network models for forecasting and control of mental health trajectories in digital applications
npj Digital Medicine, Published online: 30 December 2025; doi:10.1038/s41746-025-02252-3
Computational network models for forecasting and control of mental health trajectories in digital applicationsMetabolic signatures in gastroenteropancreatic neuroendocrine neoplasms: unraveling diagnostic and prognostic insights
Front Endocrinol (Lausanne). 2025 Dec 11;16:1676021. doi: 10.3389/fendo.2025.1676021. eCollection 2025.
ABSTRACT
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are a heterogeneous group of tumors characterized by diverse biological behaviors and variable clinical outcomes. Recent advances have highlighted the important role of metabolic reprogramming in tumorigenesis, progression, and therapeutic resistance in GEP-NENs. In this review, we synthesize the current evidence on metabolic biomarkers and altered metabolic pathways-particularly those involving glucose, lipid, and amino acid metabolism. Key biomarkers such as GLUT-1, FASN, and enzymes involved in ferroptosis, cholesterol biosynthesis, and amino acid catabolism demonstrate strong associations with tumor aggressiveness, hypoxia, and mTOR signaling. Moreover, metabolomic profiling and functional studies suggest that metabolic markers may inform prognosis and predict response to targeted therapies such as Everolimus. Although promising, the clinical translation of these markers is still limited and requires further validation in large, subtype-specific cohorts. Our findings highlight the importance of integrating metabolic profiling into the diagnostic and therapeutic landscape of GEP-NENs. Future research should prioritize biomarker standardization, multi-omics integration, and the development of metabolism-based therapeutic strategies tailored to tumor subtype and differentiation grade.
PMID:41458541 | PMC:PMC12738315 | DOI:10.3389/fendo.2025.1676021